InvestSMART

Firebrick Pharma Limited (ASX: FRE) - Announcements

- Current share price for FRE : $0.030

ASX company news and announcements for Firebrick Pharma Limited (FRE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Firebrick Pharma Limited (FRE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Firebrick Pharma Limited (FRE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Firebrick Pharma Limited (FRE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$9 Nasodine Patent Granted in Singapore 25 Oct 2022 8:40AM $0.265 $0.030 fallen by 88.68%
$9 Annual Report to Shareholders 21 Oct 2022 4:41PM $0.270 $0.030 fallen by 88.89%
$9 Letter to Shareholders & Notice of AGM & Proxy Form 21 Oct 2022 1:47PM $0.270 $0.030 fallen by 88.89%
$9 Notification of cessation of securities - FRE 10 Oct 2022 10:40AM $0.295 $0.030 fallen by 89.83%
$9 Notice of AGM and Closing Date for Director Nominations 28 Sep 2022 1:44PM $0.290 $0.030 fallen by 89.66%
$9 Firebrick announces formation of Scientific Advisory Board 14 Sep 2022 8:08AM $0.310 $0.030 fallen by 90.32%
$9 Corporate Governance Statement 23 Aug 2022 5:12PM $0.335 $0.030 fallen by 91.04%
$9 Appendix 4G 23 Aug 2022 5:12PM $0.335 $0.030 fallen by 91.04%
$9 Appendix 4E & Annual Report 23 Aug 2022 5:12PM $0.335 $0.030 fallen by 91.04%
$9 Cleansing Notice 3 Aug 2022 6:27PM $0.320 $0.030 fallen by 90.63%
$9 Application for quotation of securities - FRE 3 Aug 2022 6:21PM $0.320 $0.030 fallen by 90.63%
$9 June 2022 Quarterly Activity Report & Appendix 4C 29 Jul 2022 8:57AM $0.370 $0.030 fallen by 91.89%
$9 Firebrick Presents at Euroz Hartleys Healthcare Conference 26 Jul 2022 4:43PM $0.320 $0.030 fallen by 90.63%
$9 Outcome of s60 appeal for Nasodine and next steps 7 Jul 2022 6:23PM $0.260 $0.030 fallen by 88.46%
$9 Trading Halt 7 Jul 2022 9:31AM $0.260 $0.030 fallen by 88.46%
$9 Notification of cessation of securities - FRE 22 Jun 2022 11:46AM $0.290 $0.030 fallen by 89.66%
$9 Initial Director's Interest Notice - Richard Treagus 1 Jun 2022 8:53AM $0.365 $0.030 fallen by 91.78%
$9 Proposed issue of securities - FRE 25 May 2022 9:32AM $0.385 $0.030 fallen by 92.21%
$9 Nasodine Patent Granted in Malaysia 25 May 2022 8:34AM $0.385 $0.030 fallen by 92.21%
$9 Firebrick Appoints Dr Richard Treagus as Director 25 May 2022 8:25AM $0.385 $0.030 fallen by 92.21%
$9 Firebrick starts Phase 3 common cold trial of Nasodine 3 May 2022 1:22PM $0.405 $0.030 fallen by 92.59%
$9 March 2022 Quarterly Activity Report & Appendix 4C 26 Apr 2022 5:07PM $0.455 $0.030 fallen by 93.41%
$9 Firebrick starts COVID-19 trial of Nasodine 26 Apr 2022 9:59AM $0.460 $0.030 fallen by 93.48%
$9 Investor Presentation - Euroz Hartleys Rottnest Conference 11 Mar 2022 12:26PM $0.415 $0.030 fallen by 92.77%
$9 Investor Presentation - Euroz Hartleys Rottnest Conference 11 Mar 2022 12:19PM $0.415 $0.030 fallen by 92.77%

276 - 300 of 523 results

Page 12 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.